Clinical Trials Directory
Recruiting
Conditions
Sponsors
Search
About
Trials
/
Sponsors
/ Aeglea Biotherapeutics
Aeglea Biotherapeutics
Industry · 8 registered clinical trials.
Status
Trial
Phase
Started
Terminated
A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency
Arginase I Deficiency, Hyperargininemia
Phase 3
2023-04-04
Terminated
A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency
Homocystinuria Due to Cystathionine Beta-Synthase Deficiency
Phase 1 / Phase 2
2021-05-13
Completed
Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency
Arginase I Deficiency, Hyperargininemia
Phase 3
2019-04-10
Completed
Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer
Small-cell Lung Cancer
Phase 1 / Phase 2
2017-12-21
Completed
A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency
Arginase I Deficiency, Hyperargininemia
Phase 2
2017-12-07
Completed
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Phase 2
2016-08-01
Completed
A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency
Arginase I Deficiency, Hyperargininemia
Phase 1 / Phase 2
2016-06-01
Completed
A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors
Advanced Cancers
Phase 1 / Phase 2
2015-10-01